Korys invests in Biocartis

 

Biocartis completes EUR 71 million (USD 100 million) Series C Fund Raising

Funds will be used to commercialize a fully automated, compact molecular diagnostics system designed to drive the widespread adoption of personalized medicine and other diagnostic applications including the fight against infectious disease

Lausanne (Switzerland) – November 17, 2011.

Biocartis, a company developing and commercializing compact molecular diagnostic (MDx) systems designed to drive the widespread adoption of personalized medicine and other applications including the improved diagnosis of infectious disease, announced today the completion of EUR 71 million (USD 100 million) Series C equity fund raising backed by existing investors, new investors and industrial collaborators and partners. Investors in the round were Debiopharm Group™, Philips, Johnson & Johnson Development Corporation (JJDC), the Wellcome Trust, Korys (investment holding of the Colruyt family), Valiance, Biovest, the family office of Dr Paul Janssen, IHL SA (Luc Verelst), PMV, New Rhein Healthcare, certain members of the Biocartis senior management team and the family office of founder Rudi Pauwels (Benaruca).